Study summary

Targeted therapy plus chemo doubled survival in BRAF V600E colorectal cancer

BREAKWATER trial (encorafenib for BRAF) · Phase 3 · Published May 2025, New England Journal of Medicine

30.3months median survival, vs 15.1 with standard care

What was tested

Encorafenib (a BRAF-blocking pill) plus cetuximab and FOLFOX chemotherapy against standard chemotherapy, as first treatment for metastatic colorectal cancer with a BRAF V600E mutation (about 1 in 12 cases).

What they found

What it means

Now a first-line standard for BRAF V600E metastatic colorectal cancer.

N Engl J Med, via PubMed ↗ Trial record NCT04607421 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.